Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics

Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets

(2021) Mohammad H. Al-Shaer et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

To estimate or to forecast? Lessons from a comparative analysis of four Bayesian fitting methods based on nonparametric models

(2021) Sylvain Goutelle et al.   THERAPEUTIC DRUG MONITORING

Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis

(2021) Antonin Praet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of cefepime toxico-dynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines.

(2021) Cindy LAU et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

(2020) Jiajun Liu et al.   CLINICAL PHARMACOKINETICS

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing

(2020) Mohammad H. Al-Shaer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Use in US Hospitals: Comparison of Results From Emerging Infections Program Prevalence Surveys, 2015 and 2011

(2020) Shelley S Magill et al.   CLINICAL INFECTIOUS DISEASES

Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data

(2019) João A. Abrantes et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study

(2019) L. Boschung-Pasquier et al.   CLINICAL MICROBIOLOGY AND INFECTION

Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori PK/PD target attainments in individual patients

(2019) Clément Boidin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity

(2016) Nathaniel J. Rhodes et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation

(2016) Laura Whited et al.   PHARMACOTHERAPY

Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies

(2015) Fekade Bruck Sime et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study

(2015) Angela Huttner et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy

(2014) T. W. Felton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

(2014) J. A. Roberts et al.   CLINICAL INFECTIOUS DISEASES

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Some Comments and Suggestions Concerning Population Pharmacokinetic Modeling, Especially of Digoxin, and Its Relation to Clinical Therapy

(2012) Roger W. Jelliffe   THERAPEUTIC DRUG MONITORING

Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R

(2012) Michael N. Neely et al.   THERAPEUTIC DRUG MONITORING

High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function

(2010) F. Lamoth et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY